#USA #New York #Rosen Law Firm #Zenas BioPharma #IPO Class Action

Zenas BioPharma Investors Take Action

On June 6, 2025, the Rosen Law Firm, a prominent advocate for investor rights, announced crucial details about a class action lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO). This lawsuit is particularly relevant for investors who have incurred losses exceeding $100,000 during the company's initial public offering (IPO) held in September 2024.

Understanding the Lawsuit

The core of the legal action arises from allegations against Zenas BioPharma regarding inaccuracies in their Registration Statement associated with their IPO. According to the complaint, the Registration Statement reportedly contained false or misleading assertions and did not adequately disclose crucial information about the company's financial health. Specifically, it was claimed that Zenas BioPharma had significantly overstated their financial projections and the sustainability of their operations, relying on existing cash and expected IPO proceeds.

When the true financial situation became evident to the market, many investors faced substantial losses. This lawsuit seeks to provide restitution for affected investors who purchased Zenas BioPharma securities under potentially misleading circumstances.

Key Dates and Actions

The Rosen Law Firm has set a critical deadline of June 16, 2025, for investors wishing to serve as lead plaintiffs in the class action. A lead plaintiff acts on behalf of the wider group of investors, directing the litigation. Investors wishing to participate are encouraged to take immediate action by either submitting their information through the Rosen Law Firm's dedicated portal or by contacting attorney Phillip Kim directly.

Steps to Get Involved

1. Visit the Rosen Law Firm Website: Interested investors can visit Rosen Law Firm's site to find information on how to join the class action.
2. Contact the Firm: For more personalized assistance, investors can reach out to Phillip Kim at 866-767-3653 or via email.

Why Select the Rosen Law Firm?

The Rosen Law Firm stands out in the legal community due to its extensive experience in handling securities class actions. According to their press release, the firm has achieved significant settlements for investors, including the largest securities class action settlement against a Chinese company at that time. They were recognized as the top firm by ISS Securities Class Action Services for the number of settlements reached in 2017 and have consistently ranked within the top four firms for similar achievements since then.

Noteworthy Achievements

• - Restitution for Investors: The firm has recovered hundreds of millions of dollars for investors in past cases, showcasing its prowess in advocating for clients.
• - Expert Legal Representation: Many of the firm's attorneys have earned accolades from prestigious organizations such as Lawdragon and Super Lawyers, ensuring that clients receive the expertise they deserve during litigation.

The Bigger Picture

This class action represents an opportunity for Zenas BioPharma investors to potentially recover losses incurred due to the company's alleged misrepresentations. Rosen Law Firm emphasizes the importance of selecting qualified legal counsel to navigate these complexities successfully. As more information unravels, investors are encouraged to stay informed and engaged.

Investing in shares involves risks, and understanding your rights is paramount. Stay updated by following the Rosen Law Firm on platforms like LinkedIn, Twitter, and Facebook for regular updates on the ongoing developments of this class action.

• ---

For those affected by the IPO's fallout, joining this class action may provide a pathway to receive the compensation they rightfully deserve, all without incurring out-of-pocket legal fees upfront, thanks to the contingency payment structure offered by the Rosen Law Firm.